Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa

Bone

Volumn 45, Issue 3, 2009, Pages 493-498

  Misra, Madhusmita ^a,b   McGrane, Jacob ^a   Miller, Karen K ^a   Goldstein, Mark A ^b   Ebrahimi, Seda ^c   Weigel, Thomas ^d   Klibanski, Anne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Cambridge Eating Disorders Center   (United States)

^d MCLEAN HOSPITAL   (United States)

Author keywords

Adolescents; Anorexia nervosa; Bone metabolism; Bone turnover markers; IGF 1

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANOREXIA NERVOSA; ARTICLE; BONE TURNOVER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG ACTIVITY; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOGLYCEMIA; NAUSEA; OSSIFICATION; OSTEOLYSIS; SCHOOL CHILD;

ADOLESCENT; ANOREXIA NERVOSA; BIOLOGICAL MARKERS; BONE DENSITY; COLLAGEN TYPE I; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; OSTEOGENESIS; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; RECOMBINANT PROTEINS;

EID: 67949084970     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.06.002     Document Type: Article

References (34)

1. Lucas A.R., Beard C.M., O'Fallon W.M., and Kurland L.T. 50-year trends in the incidence of anorexia nervosa in Rochester, MN: a population-based study. Am. J. Psychiatry 148 (1991) 917-922
2. Pope Jr. H., Hudson J., and Yurgelun-Todd D. Prevalence of anorexia nervosa and bulimia in three student populations. Int. J. Eat. Disord. 3 (1984) 45-51
3. Bachrach L., Guido D., Katzman D., Litt I., and Marcus R. Decreased bone density in adolescent girls with anorexia nervosa. Pediatrics 86 (1990) 440-447
4. Misra M., Aggarwal A., Miller K.K., Almazan C., Worley M., Soyka L.A., et al. Effects of anorexia nervosa on clinical, hematologic, biochemical, and bone density parameters in community-dwelling adolescent girls. Pediatrics 114 (2004) 1574-1583
5. Biller B., Saxe V., Herzog D., Rosenthal D., Holzman S., and Klibanski A. Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J. Clin. Endocrinol. Metab. 68 (1989) 548-554
6. Misra M., Miller K., Almazan C., Ramaswamy K., Lapcharoensap W., Worley M., et al. Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J. Clin. Endocrinol. Metab. (2004) [Submitted]
7. Misra M., Miller K., Bjornson J., Hackman A., Aggarwal A., Chung J., et al. Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J. Clin. Endocrinol. Metab. 88 (2003) 5615-5623
8. Misra M., Miller K., Stewart V., Hunter E., Kuo K., Herzog D., et al. Ghrelin and bone metabolism in adolescent girls with anorexia nervosa and healthy adolescents. J. Clin. Endocrinol. Metab. 90 (2005) 5082-5087
9. Misra M., Miller K., Tsai P., Gallagher K., Lin A., Lee N., et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J. Clin. Endocrinol. Metab. 91 (2006) 1027-1033
10. Hashizume K., Suzuki S., Komatsu A., Hiramatsu K., Mori J., Yamazaki M., et al. Administration of recombinant human growth hormone normalizes GH-IGF1 axis and improves malnutrition-related disorders in patients with anorexia nervosa. Endocr. J. 54 (2007) 319-327
11. Riggs B.L., Khosla S., and Melton III L.J. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23 (2002) 279-302
12. Klibanski A., Biller B., Schoenfeld D., Herzog D., and Saxe V. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J. Clin. Endocrinol. Metab. 80 (1995) 898-904
13. Strokosch G.R., Friedman A.J., Wu S.C., and Kamin M. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study. J. Adolesc. Health 39 (2006) 819-827
14. Giustina A., Mazziotti G., and Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29 (2008) 535-559
15. Nakasaki M., Yoshioka K., Miyamoto Y., Sasaki T., Yoshikawa H., and Itoh K. IGF-I secreted by osteoblasts acts as a potent chemotactic factor for osteoblasts. Bone 43 (2008) 869-879
16. Ohlsson C., Bengtsson B., Isaksson O., Andreassen T., and Slootweg M. Growth hormone and bone. Endocr. Rev. 19 (1998) 55-79
17. Cara J., Rosenfield R., and Furlanetto R. A longitudinal study of the relationship of plasma somatomedin-C concentration to the pubertal growth spurt. Am. J. Dis. Child. 141 (1987) 562-564 [May]
18. Soyka L., Misra M., Frenchman A., Miller K., Grinspoon S., Schoenfeld D., et al. Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. J. Clin. Endocrinol. Metab. 87 (2002) 4177-4185
19. Grinspoon S., Baum H., Lee K., Anderson E., Herzog D., and Klibanski A. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J. Clin. Endocrinol. Metab. 81 (1996) 3864-3870
20. Grinspoon S., Baum H., Peterson S., and Klibanski A. Effects of rhIGF-I administration on bone turnover during short-term fasting. J. Clin. Invest. 96 (1995) 900-906
21. Mora S., Pitukcheewanont P., Kaufman F.R., Nelson J.C., and Gilsanz V. Biochemical markers of bone turnover and the volume and the density of bone in children at different stages of sexual development. J. Bone Miner. Res. 14 (1999) 1664-1671
22. Diagnostic and statistical manual of mental disorders. 34d ed., revised 1987 (1987), American Psychiatric Association, Washington, D.C. 65-67
23. Greulich W., and Pyle S. Radiographic atlas of skeletal development of the hand and wrist. 2nd ed (1959), Stanford University Press, Stanford
24. Grinspoon S., Thomas L., Miller K., Herzog D., and Klibanski A. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J. Clin. Endocrinol. Metab. 87 (2002) 2883-2891
25. Chernausek S.D., Backeljauw P.F., Frane J., Kuntze J., and Underwood L.E. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J. Clin. Endocrinol. Metab. 92 (2007) 902-910
26. Case Records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Normal reference laboratory values (see comments). N. Engl. J. Med. 327 (1992) 718-724
27. Bachrach L. Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol. Metab. 12 (2001) 22-28
28. Soyka L., Grinspoon S., Levitsky L., Herzog D., and Klibanski A. The effects of anorexia nervosa on bone metabolism in female adolescents. J. Clin. Endocrinol. Metab. 84 (1999) 4489-4496
29. Misra M., Prabhakaran R., Miller K.K., Goldstein M.A., Mickley D., Clauss L., et al. Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. J. Clin. Endocrinol. Metab. 93 (2008) 1292-1297
30. Hotta M., Shibasaki T., Sato K., and Demura H. The importance of body weight history in the occurrence and recovery of osteoporosis in patients with anorexia nervosa: evaluation by dual X-ray absorptiometry and bone metabolic markers. Eur. J. Endocrinol. 139 (1998) 276-283
31. Misra M., Prabhakaran R., Miller K.K., Goldstein M.A., Mickley D., Clauss L., et al. Weight gain and restoration of menses as predictors of bone mineral density change in adolescent girls with anorexia nervosa-1. J. Clin. Endocrinol. Metab. 93 (2008) 1231-1237
32. Horwitz M.J., Tedesco M.B., Sereika S.M., Garcia-Ocana A., Bisello A., Hollis B.W., et al. Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study. Osteoporos. Int. 17 (2006) 225-230
33. Plotkin H., Gundberg C., Mitnick M., and Stewart A.F. Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis. J. Clin. Endocrinol. Metab. 83 (1998) 2786-2791
34. Bilezikian J.P. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr. Osteoporos. Rep. 6 (2008) 24-30